Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
費城，2024年11月26日（環球新聞通訊）--世紀生物治療公司（納斯達克：IPSC），一家創新的生物技術公司，正在開發來源於誘導多能幹細胞（iPSC）的細胞療法，應用於免疫腫瘤學和自身免疫疾病，今日宣佈管理團隊成員將參加2024年12月4日星期三派傑投資第36屆年度醫療會議的以下活動：
-
Autoimmune Disease Cell Therapy Panel: 3:00 PM ET
- Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
-
Fireside Chat: 4:30 PM ET
- Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer
- 自身免疫疾病細胞療法小組：東部時間下午3點
- 演講者：查德·考恩，博士，首席科學官
- 爐邊談話：東部時間下午4點30分
- 演講者：布倫特·普費芬伯格，藥學博士，首席執行官，和查德·考恩，博士，首席科學官
A live webcast of the fireside chat can be accessed on the "Events & Presentations" page in the "Investors" section of the Company's website at . A replay of the webcast will be available for 90 days following the event.
可以在公司網站的「投資者」部分的「活動與演示」頁面訪問爐邊談話的直播網絡廣播。活動結束後，網絡廣播將可供觀看90天。
About Century Therapeutics
關於百年細胞
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .
Century Therapeutics（納斯達克：IPSC）正在利用成人幹細胞的力量開發治療性細胞療法產品，用於治療癌症和自身免疫性疾病，我們相信這將幫助我們克服第一代細胞療法的侷限性。我們通過遺傳工程和iPSC衍生細胞產品候選品的設計，專門針對血液系統和實體腫瘤癌症，擴展到自身免疫性疾病的廣泛應用。我們利用我們在細胞重編程、遺傳工程和製造領域的專業知識，開發具有潛力克服細胞治療領域許多挑戰的治療方案，並比現有的細胞治療技術具有重大優勢。我們相信我們致力於開發現貨細胞療法將擴大患者的接觸面，併爲推進癌症和自身免疫性疾病治療提供無與倫比的機會。如需了解更多有關Century Therapeutics的信息，請訪問。
For More Information:
更多信息：
Investor Relations & Media Contacts
投資者關係和媒體聯繫
Century Therapeutics
Katja Buhrer
SVP, Head of Corporate Affairs and Strategy
katja.buhrer@centurytx.com
917-969-3438
世紀治療
Katja Buhrer
企業事務與策略總監
katja.buhrer@centurytx.com
917-969-3438
Argot Partners
Noor Pahlavi
century@argotpartners.com
212-600-1902
阿哥特合夥人。
諾爾·帕赫拉維
century@argotpartners.com
212-600-1902
譯文內容由第三人軟體翻譯。
